Lumida
/DGX
⌘K
Quest Diagnostics Inc

Quest Diagnostics Inc

DGX
$235.02USD+1.68%+3.88 today

MARKET CAP

25.9B

P/E (TTM)

26.0x

FWD P/E

DAY RANGE

$229 – $235

52W RANGE

$171
$247

AI Summary

Stalk
StalkMedium

DGX remains in a constructive long- and medium-term uptrend but is experiencing a short-term pullback below the 9-day and 20-day EMAs into the 50-day SMA support. RSI is approaching oversold territory while the 50-day SMA held on the last pullback, indicating potential stabilization without a clear reversal yet. The medium-term bias remains bullish, but short-term execution is unfavorable—defer entries and stalk for a reclaim of the EMA zone or acceptance at the 50-day SMA support.

  • Q2 2026 revenue $3.04 B (+10.2% YoY)
  • FY 2026 revenue guidance up to $11.95–12.05 B (≈8.3–9.2% growth)
  • Potential PAMA payment cuts threaten 2027 revenues and margins
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$10.8B$9.9B$9.3B$9.9B$11.0B
YoY %+14.3%-8.4%-6.4%+6.7%+11.8%
P / Sales2.1x1.9x1.7x1.7x1.8x
EV / Sales2.6x2.5x2.5x2.6x2.5x
Gross Profit, Adj.$4.2B$3.4B$3.1B$3.2B$3.7B
YoY %+15.9%-18.4%-11.1%+6.3%+13.0%
Margin %39.0%34.7%33.0%32.9%33.2%
EV / Gross Profit6.7x7.3x7.5x7.9x7.7x
EBITDA, Adj.$2.8B$1.9B$1.7B$1.8B$2.1B
YoY %+19.6%-33.1%-6.6%+5.6%+14.9%
Margin %25.9%18.9%18.8%18.6%19.2%
EV / EBITDA10.2x13.3x13.1x14.0x13.3x
EBIT$2.4B$1.4B$1.3B$1.3B$1.5B
YoY %+20.8%-40.0%-8.8%+3.4%+14.6%
Margin %22.1%14.4%14.1%13.6%14.0%
EV / EBIT11.9x17.4x17.6x19.1x18.2x
Net Income$2.0B$942.0M$850.0M$866.0M$988.0M
YoY %+39.5%-52.6%-9.8%+1.9%+14.1%
Net Margin18.4%9.5%9.2%8.8%9.0%
EPS (GAAP)$15.55$7.97$7.49$7.69$8.75
YoY %+48.5%-48.7%-6.0%+2.7%+13.8%